“Current support for the feasibility study is only a small fraction of the cost needed to develop commercial prototypes, conduct comprehensive clinical trials and obtain full FDA approval. The company needs much more in future grants and investments to eventually bring our technology to clinical market and to the bedside."

"Other diseases can be detected by molecular targeting of circulating markers using conjugated nanoparticles as high-contrast photoacoustic agents. Cytophone can guide highly localized laser destruction of circulating tumor and infected cells to potentially prevent metastasis and sepsis."